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Abstract
Summary In Switzerland, the total number and incidence
of hospitalizations for major osteoporotic fractures
increased between years 2000 and 2007, while hospital-
izations due to hip fracture decreased. The cost impact of
shorter hospital stays was offset by the increasing cost per
day of hospitalization.
Introduction The aim of the study was to establish the
trends and epidemiological characteristics of hospitaliza-
tions for major osteoporotic fractures (MOF) between years
2000 and 2007 in Switzerland.
Methods Sex- and age-specific trends in the number and
crude and age-standardized incidences of hospitalized MOF
(hip, clinical spine, distal radius, and proximal humerus) in
women and men aged ≥45 years were analyzed, together
with the number of hospital days and cost of hospitaliza-
tion, based on data from the Swiss Federal Statistical Office
hospital database and population statistics.
Results Between 2000 and 2007, the absolute number of
hospitalizations for MOF increased by 15.9% in women
and 20.0% inmen, mainly due to an increased number of non-
hip fractures (+37.7% in women and +39.7% in men).
Hospitalizations for hip fractures were comparatively stable
(−1.8% in women and +3.3% in men). In a rapidly aging
population, in which the number of individuals aged ≥45 years
grew by 11.1% (women) and 14.6% (men) over the study
period, the crude and age-standardized incidences of hospital-
izations decreased for hip fractures and increased for non-hip
MOF, both in women and men. The length of hospital stay
decreased for all MOF in women and men, the cost impact of
which was offset by an increase in the daily costs of
hospitalization.
Conclusions Between years 2000 and 2007, hospitaliza-
tions for MOF continued to increase in Switzerland, driven
by an increasing number and incidence of hospitalizations
for non-hip fractures, although the incidence of hip
fractures has declined.
Keywords Cost . Epidemiology . Fractures . Hip .
Osteoporosis . Switzerland
Introduction
Osteoporosis is defined as “a systemic skeletal disease
characterized by low bone mass and microarchitectural
deterioration of bone tissue, with a consequent increase in
bone fragility and susceptibility to fracture” [1]. While
according to this definition a patient with osteoporosis is at
increased risk for fracture at any site, “typical” osteoporotic
fractures occur at the hip, spine, distal forearm, and
proximal humerus. The latter are also referred to as major
osteoporotic fractures [2–4].
Several recent publications have indicated a possible
reversal of the secular trend of hip fractures in the USA [5–
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7], Canada [8, 9], Japan [10], Finland [11], Denmark [12],
France [13], and in the region of Geneva, Switzerland [14,
15] but not in Austria [16], Spain [17], or Germany [18,
19]. None of these publications reported trends of major
osteoporotic fractures other than hip fractures.
The aim of the present analysis was to review the trends
and epidemiological characteristics of major osteoporotic
fractures in Switzerland, in female and male patients aged
45 years or older, between years 2000 and 2007. Predefined
parameters of interest were absolute number and incidence
of fracture hospitalizations, number of hospital days due to
fractures, and cost of hospitalizations for major osteoporotic
fractures.
Methods
We chose to report the characteristics of major osteopo-
rotic fractures instead of fractures due to osteoporosis
derived from all fractures multiplied by an osteoporosis
attribution rate used in earlier publications [20, 21]. In
year 2000, 51% and 24% of all hospitalizations for
fracture in women and men, respectively, were attributed
to osteoporosis [20]. Not using the attribution rates, as in
the present approach, leads to a total number of fractures
leading to hospitalization due to major osteoporotic
fractures in year 2000 corresponding to only 77% and
72% of the attributed fractures in women and men,
respectively. Therefore, the absolute numbers, incidences,
hospital days, and related costs detailed in the following
analysis should be considered conservative.
Source of hospital statistics
The administrative and medical statistics database of the
Swiss Federal Statistical Office (SFSO) was used. All Swiss
acute hospitals, rehabilitation centers, and specialized
clinics are obliged to supply their administrative (finance,
human resources, number of beds, and patient admissions)
and medical data (age, sex, number of hospitalized fractures
coded in accordance with the International Classification of
Diseases 10th Edition (ICD-10) requirements, and duration
of hospitalization) to the SFSO. Data collection is initiated
and coordinated by the SFSO following stringent quality
control measures. Since 1998, each reporting hospital uses
a plausibility testing software (currently MedPlaus version
5.0) developed by the SFSO [22]. More than 700
plausibility checks in 4 categories (single variable testing,
pooled variable testing (cross-schecks), multiple interde-
pendent variable testing, diagnostic code vs. treatment code
testing) are performed. Generated log files categorize
findings as “errors” for mandatory correction, “alerts” for
recommended correction, and “notes” for optional correc-
tion. The corrected dataset is sent to the corresponding
cantonal health department which ensures consistency in
reporting across hospitals within a canton. Inconsistencies
are returned to the reporting hospital for correction in line
with source data and cantonal requirements. Thereafter, the
datasets are sent by all cantons to the SFSO, which
performs the last plausibility testing at the federal level,
ensuring consistency across cantons. As an example, in
year 2001, at the federal level, 4.6% of the diagnostic codes
were identified as not plausible [23]. Only medical data
from Swiss acute hospital settings were retained for the
present analysis. Data from rehabilitation centers and
specialized clinics were excluded to prevent double count-
ing. Although reporting is mandatory, some records were
missing; the degree of completeness for all records for
years 2000–2007 was 81.2%, 84.9%, 95.0%, 94.1%,
96.2%, 98.2%, 98.5%, and 98.6%, respectively. All raw
data were extrapolated pro-rata to 100% to become
representative for Switzerland as a whole. Data on the
Swiss population structure between 2000 and 2007, split by
5-year age groups and sex, were also obtained from the
SFSO.
Hospitalized major osteoporotic fractures in years 2000
through 2007
Raw data for the number of fractures leading to hospital-
izations in the acute care setting and the corresponding
duration of hospitalization, categorized as described above,
were obtained for major osteoporotic fractures (fractures of
the hip, spine, distal radius, and proximal humerus), in
women and men aged ≥45 years. Hip fractures were
defined as fractures with ICD-10 codes S72.0 (fracture of
the femoral neck), S72.1 (pertrochanteric fracture), and
S72.2 (subtrochanteric fracture). Spine fractures were
defined as codes S22.0 (fracture of the thoracic spine),
S22.1 (multiple fractures of the thoracic spine), S32.0
(fracture of the lumbar spine), S32.7 (multiple fractures of
the lumbar spine), and S32.8 (other fractures of the lumbar
spine). Fractures of the distal forearm were defined as
S52.5 (fracture of the distal radius) and S52.6 (combined
fracture of the distal radius/ulna). Finally, fractures of the
proximal humerus were identified by the code S42.2
(fracture of the proximal humerus).
Epidemiological and health economic outcomes
The crude and age-standardized incidences of hospital-
izations, the number of patient-days spent in the hospital,
and the mean length of hospital stay (LOS) per patient were
calculated by 5-year age groups starting from age 45
onwards and by sex, for all major osteoporotic fractures
grouped into the fracture types defined above. Annual
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crude incidences per 100,000 persons in years 2000–2007
were calculated for hip fractures and non-hip major
osteoporotic fractures as defined above for each sex and
for the predefined 5-year age groups, starting from age 45
onwards. As first suggested by Lewinnek et al. [24], annual
age-standardized fracture incidences per 100,000 persons
and related 95% confidence intervals were calculated for
the same categories of sex, age, and fractures with direct
adjustment to the year 2000 age structure to control for the
rapid aging of the Swiss population and to allow for
comparison over time. The relevant number of exposed
persons was derived from the official population statistics
of the SFSO. Incidences by sex and by 5-year age group for
hip and non-hip major osteoporotic fractures (MOF) in year
2007 were compared to the corresponding incidences in
reference year 2000 by calculating the standardized
incidence rate ratio and its 95% confidence interval. Yearly
changes in age-specific fracture subgroups (hip and major
osteoporotic non-hip fractures) were assessed by sex using
a chi-square test for linear trends. All calculations were
done with the statistical software StatsDirect version 2.7.7
developed by StatsDirect Ltd, Altrincham, Cheshire, UK.
To assess the costs of fracture hospitalization in 2000–
2007, specific assumptions and methods were applied as
described below. As no specific cost data by fracture
diagnosis code is available, the average cost per day of
acute care hospitalization in Swiss Francs (CHF) was
obtained from the yearly hospital statistics database of the
SFSO for each year of analysis [25]. The cost per day
utilized for each year was not inflation adjusted.
Results
Swiss population structure
Between 2000 and 2007, the number of women and men in
the Swiss population increased, from 3.67 million to 3.85
million and from 3.51 million to 3.70 million, respectively,
representing an average annual population increase during
this period of 0.6% for all women and 0.7% for all men.
For both sexes, however, the number of individuals aged
≥45 years grew faster than the total population (by 11.1%
and 14.6% in women and men, respectively, over the study
period), so that as a proportion of the total population, this
age group increased from 42.1% to 44.7% (women) and
from 37.9% to 41.2% (men).
Hospitalizations for major osteoporotic fractures
Between 2000 and 2007, the absolute number of acute care
hospitalizations for major osteoporotic fractures in patients
aged ≥45 years increased by 15.9% in women and 20.0% in
men (Table 1), driven mainly by increases in the number of
hospitalizations for non-hip fractures (37.7% and 39.7%,
respectively). The corresponding changes in the number of
hip fracture hospitalizations were −1.8% in women and
+3.3% in men. The number of hospitalizations for hip
fractures decreased by 0.2% per year in women and
increased by 0.4% per year in men. In contrast, the number
of hospitalizations for major osteoporotic fractures other
than hip fractures increased by 4.1% per year in women and
by 4.3% per year in men during the same period.
As shown in Tables 2 (women) and 3 (men), the overall
age-standardized incidence of hospitalizations for hip frac-
tures per 100,000 person-years in patients aged ≥45 years
had significantly decreased by 14% in year 2007 compared
to year 2000, both in women (from 496 (95% CI 485 to 507)
to 428 (95% CI 419 to 438)) and in men (from 191 (95% CI
183 to 198) to 164 (95% CI 158 to 171)). The linear trend of
decrease during the 8 years of observation was significant in
both sexes (P=0.002 in women and P=0.001 in men, in
Figs. 1 and 2, respectively). Significant decreases in hip
fracture incidences were observed in women older than
65 years of age and in 65–79-year-old men. The largest
decreases in hip fracture incidence were observed in 65–74-
year-old women and men, reaching −26% and −24%,
respectively. Conversely, the age-standardized incidence of
hospitalizations for non-hip major osteoporotic fractures was
significantly increased in year 2007 compared to 2000 in
both sexes, by 23% in women (from 405 (95% CI 395 to
415) to 499 (95% CI 488 to 510) per 100,000 person-years)
and by 20% in men (from 160 (95% CI 153 to 167) to 193
(95% CI 186 to 200) per 100,000 person-years). The
linear trend of increase during the 8 years of observation
was significant in women (P<0.001, Fig. 1) but not in
men (P=0.149, Fig. 2). Significant increases in age-
standardized non-hip MOF were observed in all age
groups in women (Table 2) and in selected age groups
(55 to 59, 65 to 74, and ≥80 years) in men (Table 3). The
largest increase in non-hip MOF incidence was observed
in 55–64-year-old women, reaching +44% and in men
after the age of 70, reaching +48%.
Patient-days in hospital and mean length of stay
The number of patient-days per year spent in acute
hospital settings for major osteoporotic fractures in patients
aged ≥45 years decreased from 224,244 in 2000 to 185,010 in
2007 in women (a decrease of 17.5%) and from 71,477 to
62,904 in men (−12.0%) (Table 4). The decreasing trend
during the 8-year observation period was significant in both
sexes (P<0.001). The annual percent change in patient-days
over the period was −2.4% for women and −1.6% for men.
This change was due mainly to steady decreases in both
sexes in patient-days attributable to hip fractures. For other
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fractures, the changes in number of patient-days over the
period were smaller than for hip fractures.
The mean LOS for major osteoporotic fracture treatment
steadily decreased between 2000 and 2007, from 16.1 to
11.4 days in women (−29.2%) and from 15.3 to 11.2 days
in men (−26.8%). The mean annual change in LOS was
−4.2% in women and −3.8% in men, with a similar
magnitude across all fractures, so that hip fractures
remained the fracture type with the longest hospitalization
duration in year 2007.
Cost of hospitalizations for major osteoporotic fractures
As described above, the average LOS for patients hospital-
ized because of fractures decreased substantially over the
period between 2000 and 2007. The effect of this was
counterbalanced, however, by rising hospital costs: the
mean cost per day of hospitalization increased from CHF
996.00 to CHF 1,543.00, over the same period, a rise of
55%. The combined effect of these two changes was to
increase total hospital costs for all major osteoporotic
fractures from CHF 223.5 millions in year 2000 to CHF
285.4 (+27.7%) in year 2007 in women and from 71.2 to
97.1 millions (+36.4%) in men during the same period
(Table 4). These increasing trends during the 8-year
observation period did not reach statistical significance,
neither in women (P=0.086) nor in men (P=0.258). While
the costs of hip fractures increased by 2.0% and 2.5% per
year between 2000 and 2007 in women and men,
respectively, the corresponding cost of non-hip fractures
increased by 5.0% and 6.4% per year. As shown in Fig. 3,
the economic benefit of reductions in the LOS has been
offset by the higher daily cost of hospitalization—indeed,
mean cost per patient increased by 1.2% per year in women
and by 1.6% per year in men, corresponding to an overall
increase in the cost per patient hospitalized for a major
osteoporotic fracture of 10.2% (women) and 13.6% (men)
over the 8 years of observation.
Discussion
This epidemiological analysis of the hospitalization rates
and characteristics of major osteoporotic fractures (hip,
spine, distal radius, and proximal humerus) in acute
hospital settings in Switzerland suggests a nationwide
reversal of the secular trend of hip fractures. The present
results show for the first time that in a rapidly aging
population, the incidence of hospitalizations for major
osteoporotic fractures other than hip fractures followed an
opposite trend. Furthermore, the economic benefit of the
reduced duration of hospitalization for all major osteopo-
rotic fractures was offset by the simultaneous increase in
the cost per day of hospitalization.
Switzerland ranks second worldwide after Japan with
regard to the proportion of elderly in the resident population
[26]. In Switzerland, life expectancy at birth is among the
highest worldwide (82.5 years for women and 76.7 years
for men in 2001) [27] and is continuously increasing,
reaching 84.2 and 79.4 years in year 2007 in women and
men, respectively [28]. According to the demographic
scenarios from the SFSO, this increasing trend will not
level off before year 2050, by when the population older
than 65 years of age will almost have doubled [29].
Table 1 Absolute number of hospitalized major osteoporotic fractures in women and men from 2000 to 2007
2000 2001 2002 2003 2004 2005 2006 2007 Change 2007
vs 2000 (%)
Change per
year (%)
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Women
Hip 7,684 8,375 7,896 7,895 7,522 7,307 7,402 7,544 −1.8 −0.2
Spine 1,295 1,454 1,477 1,540 1,493 1,586 1,649 1,844 42.4 4.5
Distal radius 2,893 3,254 3,438 3,891 3,881 4,381 4,668 4,234 46.4 4.9
Proximal humerus 2,076 2,217 2,308 2,291 2,542 2,407 2,636 2,549 22.8 2.6
Subtotal, non-hip 6,264 6'925 7,223 7,722 7,916 8,374 8,953 8,627 37.7 4.1
Total 13,948 15,300 15,119 15,617 15,438 15,681 16,355 16,171 15.9 1.9
Men
Hip 2,538 2,667 2,567 2,592 2,527 2,448 2,622 2,623 3.3 0.4
Spine 854 911 821 929 962 950 1,010 1,150 34.7 3.8
Distal radius 635 719 752 857 829 936 1,009 958 50.9 5.3
Proximal humerus 643 778 699 761 793 926 855 871 35.5 3.9
Subtotal, non-hip 2,132 2,408 2,272 2,547 2,584 2,812 2,874 2,979 39.7 4.3
Total 4,670 5,075 4,839 5,139 5,111 5,260 5,496 5,602 20.0 2.3
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Therefore, the current trend indicating a reduction of hip
fracture incidence will not be sufficient to reduce in the
number of hip fractures in the coming decades. Further-
more, any reduction in hip fracture incidence may be more
than offset by the increasing incidences of hospitalizations
of major osteoporotic fractures other than hip.
The incidence of hip fractures decreased in all age
groups between year 2000 and year 2007, indicating that
the reported reversal of the secular trend of hip fractures in
the region of Geneva between years 1991 and 2000 [14]
may be a nationwide phenomenon that continued at least
until year 2007. Patients with hip fractures are usually
hospitalized for surgical repair, so that the incidence of
hospitalizations may be considered as a reliable approxi-
mation of their overall incidence. As already done by others
who reported similar findings [8, 12, 14], we can only
speculate about the potential causes of such a reversal.
First, this decreasing incidence was observed in both sexes,
although more pronounced in women than in men. Second,
it was observed in all age groups, although most pro-
nounced in 65–74-year-old women and in 45–64-year-old
men. This is consistent with earlier observations from
Sweden that indicated a right-shift of the hip fracture
incidence curve in women [30]. Women in this age group
may have benefited from the “golden days” of hormone
replacement therapy, which was shown to reduce the risk of
hip fracture, until safety concerns regarding the HRT-
induced increased risk of breast cancer, stroke, nonfatal
myocardial infarction, and pulmonary embolism [31, 32]
gained considerable public attention and led many physi-
cians and women, including those in Switzerland, to restrict
their usage [33]. This age group is also the typical category
of the population in which osteoporosis is diagnosed and
treated with a bone active substance proven to reduce
fracture risk at the hip, generally a bisphosphonate [34, 35].
However, as suggested by others, the decrease in hip
fractures may be much too large to be explained solely by
an increase in the use of osteoporosis treatment [8, 12, 36].
Furthermore, a reduction in hip fracture incidence was also
observed in men who are not the primary target group for
interventions against osteoporosis in Switzerland. The
awareness and use of vitamin D in the elderly and very
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old may have increased, especially in nursing homes, since
vitamin D supplementation was first shown to reduce hip
fractures in institutionalized elderly [37]. Similarly, one may
speculate that the use of hip protectors [38–40] and the
dissemination of information about fall prevention measures
[41, 42] may have contributed to the decrease. However, the
largest decrease in incidence was not seen in patients aged
85 years or older. Finally, the prevalence of osteoporosis
itself may simply be declining, as suggested by the latest
findings of the NHANES 2005–2006 survey which showed
a decrease of the age-adjusted prevalence of osteoporosis
measured by DXA at the femoral neck of 7% in women and
3% in men compared to the NHANES III (1988–1994)
survey [43]. No similar data are available for Switzerland.
The incidence of hospitalizations of major osteoporotic
fractures other than of the hip increased during the same
period in both sexes and in all age groups. This finding
contrasts with earlier reports from Finland which indicated
that low-trauma knee [44], ankle [45], and distal humeral
Table 4 Patient-days spent in acute care hospitals and annual cost of hospitalizations (in millions CHF) for major osteoporotic fractures in Switzerland
2000 2001 2002 2003 2004 2005 2006 2007 Change 2007
vs. 2000 (%)
Change per
year (%)
Patient-days
Women
Hip 146,302 149,380 141,410 138,974 124,271 116,910 110,475 110,819 −24.3 −3.4
Spine 21,600 21,484 24,630 24,082 20,693 21,279 22,064 22,624 +4.7 +0.6
Distal radius 25,200 26,868 23,929 23,934 24,453 25,003 25,755 23,767 −5.7 −0.7
Proximal humerus 31,143 31,459 30,536 28,520 29,406 27,627 29,777 27,798 −10.7 −1.4
Total days 224,244 229,192 220,506 215,510 198,823 190,818 188,071 185,010 −17.5 −2.4
Men
Hip 47,840 45,802 44,625 43,341 40,110 37,144 39,484 37,735 −21.1 −2.9
Spine 11,830 12,300 11,228 11,472 11,073 9,981 11,423 11,901 +0.6 +0.1
Distal radius 3,820 4,372 4,160 4,864 4,427 4,929 5,045 4,559 +19.3 +2.2
Proximal humerus 7,986 8,630 7,255 8,476 8,262 8,517 8,227 8,709 +9.1 +1.1
Total days 71,477 71,105 67,268 68,153 63,872 60,571 64,179 62,904 −12.0 −1.6
Hospitalization cost (CHF, millions)
Women
Hip 145.8 170.1 174.7 180.3 166.2 165.3 161.9 171.0 +17.3 +2.0
Spine 21.5 24.5 30.4 31.2 27.7 30.1 32.3 34.9 +62.3 +6.2
Distal radius 25.1 30.6 29.6 31.1 32.7 35.3 37.7 36.7 +46.2 +4.8
Proximal humerus 31.0 35.8 37.7 37.0 39.3 39.1 43.6 42.9 +38.4 +4.1
Total 223.5 260.9 272.4 279.6 265.9 269.7 275.6 285.4 +27.7 +3.1
Men
Hip 47.7 52.1 55.1 56.2 53.7 52.5 57.9 58.2 +22.0 +2.5
Spine 11.8 14.0 13.9 14.9 14.8 14.1 16.7 18.4 +55.9 +5.7
Distal radius 3.8 5.0 5.1 6.3 5.9 7.0 7.4 7.0 +84.2 +8.0
Proximal humerus 8.0 9.8 9.0 11.0 11.1 12.0 12.1 13.4 +67.5 +6.8
Total 71.2 81.0 83.1 88.4 85.4 85.6 94.0 97.1 +36.4 +3.9
P value for trends: patient-days women (P<0.001) and men (P<0.001); hospitalization cost women (P=0.086) and men (P=0.258)
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[46] fractures may be stabilizing or even declining in this
country. Importantly, the present analysis reports hospital-
ized fractures only. In an earlier work, we calculated that
the hospitalization rates for all clinical spine fractures,
fractures of the distal radius, and fractures of the proximal
humerus were 22.3%, 34.1%, and 52.6% in women aged
50 years or older [3]. The corresponding figures in men
aged 50 years or older were 29.1%, 28.2%, and 41.9%,
respectively [3]. Therefore, the probability of being
hospitalized after a fracture may have increased at the
expense of ambulatory treatment. This hypothesis may
apply to clinical spine fractures, as vertebroplasties and
kyphoplasties are increasingly performed in patients with
acute painful fractures of one or more vertebral bodies [47].
However, we are not aware of revisions or extensions of the
indications for surgical repair of fractures of the radius and the
humerus during the period of observation. In addition, the
ongoing health care reform has fostered a shift from traditional
inpatient care towards preferred ambulatory outpatient care
which would rather plead in favor of a decreasing number of
hospitalizations including for fractures [48].
The cost of all hospitalizations for major osteoporotic
fractures increased in women and men over the study
period, driven mainly by large increases in the cost of non-
hip fractures. On average, the direct medical cost of
hospitalized major osteoporotic fractures was CHF 365
million per year between years 2004 and 2007, and the
mean cost per patient was approximately CHF 17,000 for
both sexes. The length of hospital stay has considerably
decreased between 2000 and 2007 for all major osteopo-
rotic fractures. While this trend may reflect efforts in
optimizing inpatient acute medical care and cost, the
present analysis shows that the cost impact of these efforts
was totally offset by the parallel increase in the average cost
per day of hospitalization. Furthermore, it is reasonable to
assume that a minimal duration of hospitalization for
surgical fracture repair exists and will be reached during
the coming years. Once this floor duration of hospitaliza-
tion is achieved, cost optimization will depend on whether
the daily cost of per day of hospitalization alone can be
reduced and possibly more realistically on the ability to
avoid hospitalizations by preventing osteoporotic fractures
through targeted interventions in populations at risk.
The present analysis showed that the total number of
fractures leading to hospitalization increased from 2000 to
2007 in a population (45 years or older) that increased in
number over the same period. This is also the first report of
an increase in incidence of major osteoporotic fractures
other than the hip, a finding that may be of considerable
relevance. Typical sites of osteoporotic fractures may vary
in their susceptibility to fracture and their response to
intervention [49–52]. This would suggest that interventions
aimed at reducing fracture risk should not only document
their efficacy against vertebral and pooled non-vertebral
fractures (including hip fractures), but also with regard to
individual major osteoporotic fractures, namely fractures of
the distal radius and the proximal humerus, and possibly
other fracture types. As a consequence, certain patients may
be shown to benefit more from certain interventions than
from others. If so, these patients could be identified by
means of a fracture site-specific risk assessment tool that
offers improvements over FRAX [2, 3]. A nationwide
fracture registry recording all hospitalized and non-
hospitalized fragility fractures and the specific patient and
fracture characteristics, including falls, would contribute to
highlight the true changes in incidence of such fragility
fractures, to study their correlation with underexplored risk
factors such as falls, and to monitor the effects of
interventions over time under “real-life” circumstances.
The present study has some limitations. The degree of
completeness of patient records reporting increased from
81.2% in 2000 to 98.6% in 2007, mainly due to new
hospitals fulfilling their obligations. A selection bias cannot
be excluded if hospitalizations for fractures were signifi-
cantly different in these hospitals. However, reporting
exceeded 95% as of 2002, so that the magnitude of such
a hypothetical bias is expectedly low. Only fracture patients
hospitalized in acute settings were considered in the present
analysis report, due to the lack of accessible fracture data in
the outpatient sector in Switzerland. Therefore, the calcu-
lated incidences do not reflect the true incidence of
osteoporotic fractures. Whether the proportions of hospital-
ized and non-hospitalized fractures reported in our earlier
work [53] are still valid also remains unknown. Finally, our
study was neither designed nor able to identify the exact
causes of the reported findings.
In the rapidly aging Swiss population, hospitalizations for
major osteoporotic fractures increased between years 2000
and 2007. The decreasing incidence of hip fractures was
overcompensated by the increasing incidences of hospital-
izations for clinical fractures of the spine, distal radius, and
proximal humerus. The reduction in the mean length of stay
observed for all fractures was offset by the accompanying
increase in the daily cost of hospitalization. Further research is
needed to confirm and better understand these trends.
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